Page 738 - Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice

726 INDEX

Fractional clearance of urea distribution volume fluid and electrolyte absorption and secretion as effective osmole, 10
(Kt/V), 682, 683, 683f in, 436–442, 436f for hyperglycemia, perioperative use of, 410
Frank-Starling curve, 349 physiology of, 436–442 for hyperkalemia, 113
Free radicals, in shock, 562 Gastrostomy feeding, 634–635, 635f, 636f for hypoglycemia, perioperative use of, 409
Free water excretion, in renal disease, 468 for acute pancreatitis, 451 in liver disease, 481–482
Fresh frozen plasma, 587. See also Transfusion for diarrhea and vomiting, 447 in peritoneal dialysate, 672–673
(s) percutaneous tube placement in renal transport of, 35–36
for acute pancreatitis, 450 endoscopic, 635, 636f Glucose degradation products, in peritoneal
for dilution coagulopathy, 597t nonendoscopic, 635–636 dialysis, 672–673
perioperative use of, 413, 428 surgical tube placement in, 634–635, 635f Glutamine cycle, 458–459, 459f, 462
for shock, 565t, 569–570 Gelatin solutions, 410, 424, 427. Glycolysis, in shock, 562, 562f
thawing of, 595 See also Hydroxyethyl starches Glycosaminoglycans, 648
Furosemide, 523f, 523t drug interactions with, 410 Goal-directed therapy, 417
for ascites, 488 perioperative use of, 424, 427 Goldman-Hodgkin-Katz constant-field
dosage and administration of, 524–525 physiochemical properties of, 424 equation, 23, 93
for heart failure, 515, 523t, 524, 529, 531 for shock, 566 Granulomatous disease, hypercalcemia in,
dosage of, 525, 531–532 Geriatric animals, perioperative management of, 153–154, 160
for refractory edema/effusions, 531–532 412 Grapes, hypercalcemia due to, 155–156
for hypercalcemia, 157–159, 158t Gibbs-Donnan equilibrium, 4 Grass tetany, 216, 218
for hyperkalemia, 114, 114b Gitelman’s variant of Barrter syndrome, Greyhounds
in renal failure, 552f 105–106 as blood donors, 589
for hypoglycemia, 509 Globulin(s), 461–462, 461f exercise-related hypochloremia in, 86
hypokalemia due to, 106–107 as acute-phase reactants, 461 Guided catheters
for oliguria, 548–549 [A tot ] and, 319 central venous, 352, 354, 365, 366.
ototoxicity of, 548–549 concentration of, 461–462 See also Intravenous catheters
resistance to, 486 in hypoalbuminemia, 464 over-the-needle, 352
for transfusion-related circulatory overload, hepatic synthesis of, 461
597t Glomerular basement membrane, 26, 28f
Glomerular capillary wall, 26–27, 28f H
+
+
Glomerular filtration, 26–31 H ,K ATPase, 97
G morphology and, 26–27, 28f H 2 -antagonists
Gallium nitrate, for hypercalcemia, 163 ultrafiltration constant and, 28–29 for diarrhea and vomiting, 446
Gases. See Blood gas(es) Glomerular filtration barrier, 26–27, 28f for metabolic alkalosis, 280
Gastric acid, secretion of, 436–437, 437f, 438f Glomerular filtration rate Haemobartonella infection, transfusion-related,
excessive, 446 arteriolar resistance and, 29, 29f,30t, 591
Gastric dilatation, 448 31–32, 31f Hair removal, for catheterization, 355
Gastric juice, 436–437, 437f, 438f compensatory increase in, 49 Hartmann’s solution. See Lactated Ringer’s
electrolytes in, 276–277, 276f, 277f, creatinine clearance and, 30 solution
+-
436–437, 437f, 438f definition of, 27–28 H ATPase, 97
chloride, 80–81, 80b determinants of, 27–29 Heart failure. See Congestive heart failure
sodium, 80–81 in heart failure, 521 Heart rate
Gastric lavage, for salicylate intoxication, 262 inulin clearance and, 30, 31 in fluid therapy monitoring, 387, 390
Gastric residual volume, in enteral nutrition, in liver disease, 468, 469, 470, 472 in hypovolemia, 418
640–641, 642–643 measurement of, 29–31 in shock, 560–561
Gastric ulceration, hypercalcemia and, 139 renal blood flow and, 29, 29f,30t, 31–33, Heatstroke
Gastric volvulus, 448 32f fluid therapy for, 334, 510–511
Gastrinomas single-nephron, 27–28 pathophysiology of, 510
diarrhea and, 445 sodium balance and, 48–49, 49f Hematocrit, in dehydration, 335, 336
vs. VIPomas, 445 Glomerular ultrafiltrate, 28 Hematologic cancers, hypercalcemia in, 147,
Gastroenteritis. See also Diarrhea; Vomiting Glomerulotubular balance, 48–49 147f, 149–150
metabolic acidosis and, 256–257, 256f, 257t Glomerulus Hemochromatosis, posttransfusion, 598
nutritional support in, 447 capillary endothelium of, 26, 28f Hemodialysis, 680–714
Gastrointestinal disorders charge selectivity of, 27, 28f acid-base balance in, 694–695
acid-base disturbances in, 446 morphology of, 26–27, 28f for acute kidney injury, 689–698
diarrhea in, 444–445 size selectivity of, 27 anticoagulation for, 696–698, 698f
fluid therapy for, 445–447 Glucagon, for hypoglycemia, 509 buffer formulation in, 694–695
fluid and electrolyte disturbances in, Glucocorticoids dialysate additives in, 695
436–455 deficiency of. See Hypoadrenocorticism dialysate composition in, 693–694, 694f
hypoproteinemia in, 447–448 for hypoadrenocorticism, 508 dialysate temperature in, 695–696
metabolic alkalosis in, 271 for hypoglycemia, 509 dialysis time in, 690–692, 692t
shock in, 446 for shock, 574–575 extracorporeal blood flow in, 692–693
vomiting in, 443–444, 443f in sodium retention in liver disease, 469 hemodialyzers for, 690, 691t
fluid therapy for, 445–447 for transfusion reactions, 597t treatment intensity in, 690, 692t
Gastrointestinal hypoperfusion, in shock, 563 Gluconate, 340, 341 adequacy of, 683
Gastrointestinal inflammation, secretagogues Gluconeogenesis, 266 quantification of, 684–688
in, 442, 442f Glucose anticoagulation for, 696–698, 698f
Gastrointestinal tract in commercial fluids, 339, 341 buffer formation in, 694–695